IDIA.SW
Price:
$0.9285
Market Cap:
$167.36M
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration wit...[Read more]
Industry
Biotechnology
IPO Date
2017-06-16
Stock Exchange
SIX
Ticker
IDIA.SW
According to Idorsia Ltd’s latest financial reports and current stock price. The company's current ROE is 30.42%. This represents a change of 306.86% compared to the average of 7.48% of the last 4 quarters.
The mean historical ROE of Idorsia Ltd over the last ten years is -117.66%. The current 30.42% ROE has changed -125.85% with respect to the historical average. Over the past ten years (40 quarters), IDIA.SW's ROE was at its highest in in the March 2022 quarter at 163.73%. The ROE was at its lowest in in the December 2021 quarter at -241.49%.
Average
-117.66%
Median
-61.77%
Minimum
-608.99%
Maximum
125.26%
Discovering the peaks and valleys of Idorsia Ltd ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.94%
Maximum Annual ROE = 125.26%
Minimum Annual Increase = -120.57%
Minimum Annual ROE = -608.99%
Year | ROE | Change |
---|---|---|
2023 | 30.75% | -75.45% |
2022 | 125.26% | -120.57% |
2021 | -608.99% | 701.03% |
2020 | -76.03% | -73.50% |
2019 | -286.85% | 393.44% |
2018 | -58.13% | 2.94% |
2017 | -1.91% | -97.07% |
The current ROE of Idorsia Ltd (IDIA.SW) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-150.99%
5-year avg
-163.17%
10-year avg
-117.66%
Idorsia Ltd’s ROE is less than VAT Group AG (28.27%), less than Lonza Group AG (6.09%), greater than Basilea Pharmaceutica AG (-19.22%), less than Straumann Holding AG (14.23%), less than Santhera Pharmaceuticals Holding AG (188.73%),
Company | ROE | Market cap |
---|---|---|
28.27% | $10.63B | |
6.09% | $39.51B | |
-19.22% | $518.79M | |
14.23% | $18.68B | |
188.73% | $104.84M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Idorsia Ltd using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Idorsia Ltd or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Idorsia Ltd's ROE?
How is the ROE calculated for Idorsia Ltd (IDIA.SW)?
What is the highest ROE for Idorsia Ltd (IDIA.SW)?
What is the 3-year average ROE for Idorsia Ltd (IDIA.SW)?
What is the 5-year average ROE for Idorsia Ltd (IDIA.SW)?
How does the current ROE for Idorsia Ltd (IDIA.SW) compare to its historical average?